{
    "brief_title": "Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Eribulin Mesylate', 'Anlotinib hydrochloride']",
    "drugs_list": [
        "Eribulin Mesylate",
        "Anlotinib hydrochloride"
    ],
    "diseases": "['HER2-negative Breast Cancer']",
    "diseases_list": [
        "HER2-negative Breast Cancer"
    ],
    "enrollment": "40.0",
    "inclusion_criteria": "inclusion criteria: \n\n The patient volunteers and signs an informed consent form; \n\n Age \u226518 years old, female; \n\n The patient was diagnosed as HER2 negative breast cancer by histopathology ( HER2 negative (IHC-/+ or IHC++ but FISH/CISH- )), and there is at least 1 measurable lesion of metastasis according to RECIST 1.1; \n\n All patients have previously underwent chemotherapy containing anthracyclines and taxanes, and received \u22651 line chemotherapy for metastatic breast cancer; \n\n Patients with hormone receptor positive (ER positive (IHC ER positive percentage \u22651%), PR positive (IHC PR positive percentage \u22651%)) have underwent \u22651 line endocrine therapy; \n\n Physical condition ECOG PS: 0-1; \n\n Laboratory tests meet the following criteria: \n\n Bone marrow function: absolute count of blood neutrophils (ANC) \u22651.5\u00d7109/L; platelet (PLT)\u2265100\u00d7109/L; hemoglobin (HB)\u226590g/L; \n\n Liver function: serum total bilirubin (STB), combined bilirubin (CB) \u2264 upper limit of normal (ULN) *1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) \u2264ULN*2.5; \n\n Renal function: serum creatinine (Cr) \u2264 ULN; endogenous creatinine clearance (Ccr) \u2265 60 ml / min (calculated using the Cockcroft-Gault formula). \n\n ",
    "exclusion_criteria": ": \n\n Previous breast cancer history (except for ipsilateral DCIS that only received local treatment \u22655 years ago), malignant tumors of other histological origins (except for non-melanoma skin cancer or cervical carcinoma in situ) unless the patient's tumor had been completely alleviated and had not received treatment for at least 5 years before the enrollment date; \n\n Major surgery within 4 weeks prior to enrollment, or surgical wounds have not healed; \n\n Embolization and bleeding occurred within 4 weeks before enrollment; \n\n Severe cardiovascular disease, including hypertension (BP\u2265160/95mmHg) uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, severe heart rhythm Abnormalities and pericardial effusions; \n\n Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; \n\n Other clinical trials of drugs were used in the first four weeks of the first medication; \n\n Subjects with treatment history of eribulin or anti-angiogenesis drugs; \n\n Suffering from mental illness, poor compliance; \n\n Researchers believe that it is not suitable for inclusion.",
    "brief_summary": "This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients.",
    "NCT_ID": "NCT04624711"
}